Roche Launches Upgraded cobas Systems 2.0 to Revolutionize Molecular Diagnostics Efficiency

Roche Launches Upgraded cobas Systems 2.0 to Revolutionize Molecular Diagnostics Efficiency

(IN BRIEF) Roche has received CE certification for its enhanced cobas® 6800/8800 systems 2.0, introducing significant improvements in laboratory diagnostics. The upgrade streamlines operations by reducing downtime, consolidating test menus, and increasing throughput, supported by innovative TAGS technology that detects up to 15 targets from a single sample. Designed for mid-to-high volume molecular testing, the system provides a unified user experience across the cobas family and addresses modern laboratory needs. Global deployment is underway, with U.S. FDA clearance expected in 2025.

(PRESS RELEASE) BASEL, 13-Dec-2024 — /EuropaWire/ — Roche has announced the CE certification of its enhanced cobas® 6800/8800 systems 2.0, marking a significant step forward in laboratory diagnostics. This latest upgrade brings improved efficiency, increased throughput, and greater flexibility to healthcare laboratories worldwide. Designed to streamline operations, the system update reduces downtime, consolidates test menus, and optimizes resource utilization, offering a more effective diagnostic experience for both healthcare providers and their patients.

“This advancement represents another milestone in Roche’s ongoing commitment to innovation in molecular testing,” said Matt Sause, CEO of Roche Diagnostics. “By combining exceptional throughput with the flexibility needed by modern laboratories, we’re enabling labs to better support physicians and deliver improved outcomes for patients.”

A Unified Approach to Diagnostics

The cobas 6800/8800 systems 2.0 now support the majority of the cobas test menu, integrating the new Temperature-Activated Generation of Signal (TAGS) technology. This cutting-edge feature allows up to 15 targets to be detected simultaneously from a single patient sample, ensuring exceptional efficiency in high-throughput molecular diagnostics. These advancements build on the capabilities of the cobas family, including the newest cobas 5800 system, to deliver a unified user experience across platforms.

Targeted at mid-to-high volume molecular testing laboratories, the upgraded cobas systems address key operational challenges by offering intelligent workflows, unmatched throughput, and proven reliability. The new technology is designed to meet the evolving needs of labs, improving their ability to handle diverse and complex diagnostic demands.

While the CE certification enables immediate global deployment, Roche plans to submit the system for U.S. FDA 510(k) clearance in 2025. This strategic expansion underscores Roche’s dedication to advancing molecular diagnostic technologies and improving healthcare outcomes on a global scale.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Media Contacts:

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

SOURCE: Roche